Home › Funds › Lion Point Capital, LP › MLYS
Lion Point Capital, LP position in MLYS
MINERALYS THERAPEUTICS INC · Health Care
Lion Point Capital, LP reported holding 10,500 shares of MLYS (MINERALYS THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$283K, representing 1.36% of its reported portfolio and ranking #27 among its reported holdings. Lion Point Capital, LP has disclosed MLYS holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Lion Point Capital, LP's MLYS position evolved
Lion Point Capital, LP first disclosed a stake in MLYS in Q1 2024 at 60,000 shares (US$775K). The position peaked in Q3 2025 at 39,000 shares, worth US$1.5M. Across 10 filings, Lion Point Capital, LP increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 6 time(s). The most recent filing (Q2 2026) shows 10,500 shares valued at US$283K. Notable position changes include a 32% increase in Q2 2024 (shares rose 4% over the following quarter), a 51% trim in Q3 2025 (shares fell 4% over the following quarter), a 73% trim in Q4 2025 (shares fell 25% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 60.00K | $774.60K | New |
| Q2 2024 | 79.00K | $924.30K | Add |
| Q3 2024 | 79.00K | $956.69K | Hold |
| Q4 2024 | 79.00K | $972.49K | Hold |
| Q1 2025 | 79.00K | $1.25M | Hold |
| Q2 2025 | 79.00K | $1.07M | Hold |
| Q3 2025 | 39.00K | $1.48M | Reduce |
| Q4 2025 | 10.50K | $381.05K | Reduce |
| Q1 2026 | 10.50K | $284.44K | Hold |
| Q2 2026 | 10.50K | $283.29K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MLYS and 13F data
MLYS (MINERALYS THERAPEUTICS INC) is a Health Care company. 54 other funds we track also report a position in MLYS — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$207.6M), Catalys Pacific, LLC (US$196.0M), Samsara BioCapital, LLC (US$158.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MLYS
- RA CAPITAL MANAGEMENT, L.P. 7.69M sh · $207.55M · Q2 2026
- Catalys Pacific, LLC 7.80M sh · $196.00M · Q3 2026
- Samsara BioCapital, LLC 5.87M sh · $158.40M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.96M sh · $106.79M · Q2 2026
- Laurion Capital Management LP 2.51M sh · $67.62M · Q2 2026
- ORBIMED ADVISORS LLC 2.11M sh · $56.94M · Q2 2026
- SR ONE CAPITAL MANAGEMENT, LP 1.56M sh · $42.20M · Q2 2026
- Andera Partners 1.59M sh · $40.00M · Q3 2026
- SPHERA FUNDS MANAGEMENT LTD. 1.47M sh · $39.66M · Q2 2026
- Ghisallo Capital Management LLC 1.12M sh · $30.35M · Q2 2026
- Logos Global Management LP 1.05M sh · $28.33M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.04M sh · $28.06M · Q2 2026
More on Lion Point Capital, LP
FAQ
How long has Lion Point Capital, LP held MLYS?
Lion Point Capital, LP has disclosed MLYS holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
What is Lion Point Capital, LP's current position in MLYS?
As of Q2 2026, Lion Point Capital, LP holds 10.50K shares of MLYS (MINERALYS THERAPEUTICS INC), valued at $283.29K, representing 1.36% of its reported portfolio and ranking #27.
Has Lion Point Capital, LP been buying or selling MLYS?
In the latest 13F filing (Q2 2026), Lion Point Capital, LP held unchanged its position in MLYS. The position peaked in Q3 2025 at 39.00K shares.
Which other funds hold MLYS?
Other major institutional holders of MLYS include RA CAPITAL MANAGEMENT, L.P., Catalys Pacific, LLC, Samsara BioCapital, LLC, among 54 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.